Kovitz Investment Group Partners
ALXN

Kovitz Investment Group Partners’s Alexion Pharmaceuticals ALXN Stock Holding History

Kovitz Investment Group Partners’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-8,979
Closed -$1.65M – 454
2021
Q2 		$1.65M Buy
8,979
+329
+4% +$56.5K 0.03% 255
2021
Q1 		$1.32M Buy
8,650
+2,380
+38% +$368K 0.03% 254
2020
Q4 		$980K Sell
6,270
-470
-7% -$60.4K 0.02% 272
2020
Q3 		$771K Buy
6,740
+95
+1% +$10.2K 0.02% 281
2020
Q2 		$746K Sell
6,645
-3,315
-33% -$352K 0.02% 280
2020
Q1 		$894K Buy
9,960
+2,475
+33% +$243K 0.03% 254
2019
Q4 		$810K Sell
7,485
-3,048
-29% -$326K 0.02% 285
2019
Q3 		$1.03M Buy
10,533
+4,465
+74% +$503K 0.03% 262
2019
Q2 		$794K Buy
6,068
+630
+12% +$81.2K 0.03% 286
2019
Q1 		$735K Buy
+5,438
New +$676K 0.02% 300

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Kovitz Investment Group Partners's ALXN Position: Q3 2021 in Review

Kovitz Investment Group Partners sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 8,979 shares — an estimated $1.65M sold.

Kovitz Investment Group Partners first reported a position in ALXN in Q1 2019 and held it in 10 quarters. The position peaked at $1.65M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Kovitz Investment Group Partners reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Kovitz Investment Group Partners sold 8,979 Alexion Pharmaceuticals shares in Q3 2021, an estimated $1.65M.
  • Kovitz Investment Group Partners first reported a position in Alexion Pharmaceuticals in Q1 2019 and held it in 10 quarters.
  • Kovitz Investment Group Partners's Alexion Pharmaceuticals position peaked at $1.65M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Kovitz Investment Group Partners's 13F filing for Q3 2021, filed 28 Oct 2021.